{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:30:14Z","timestamp":1793896214857,"version":"4.8.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00774-023-01435-w","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T01:28:38Z","timestamp":1683768518000},"page":"317-326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Management of bone metastasis in prostate cancer"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-1350","authenticated-orcid":false,"given":"Kazuo","family":"Nishimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"1435_CR1","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1007\/s00330-020-07363-x","volume":"31","author":"F Ottosson","year":"2021","unstructured":"Ottosson F, Baco E, Lauritzen PM, Rud E (2021) The prevalence and locations of bone metastases using whole-body MRI in treatment-na\u00efve intermediate- and high-risk prostate cancer. Eur Radiol 31:2747\u20132753. https:\/\/doi.org\/10.1007\/s00330-020-07363-x","journal-title":"Eur Radiol"},{"key":"1435_CR2","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1097\/01.ju.0000123981.03084.06","volume":"171","author":"S Abuzallouf","year":"2004","unstructured":"Abuzallouf S, Dayes I, Lukka H (2004) Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 171:2122\u20132127. https:\/\/doi.org\/10.1097\/01.ju.0000123981.03084.06","journal-title":"J Urol"},{"key":"1435_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12894-017-0229-z","volume":"17","author":"Y Lin","year":"2017","unstructured":"Lin Y, Mao Q, Chen B, Wang L, Liu B, Zheng X, Xie L (2017) When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? A retrospective study. BMC Urol 17:41. https:\/\/doi.org\/10.1186\/s12894-017-0229-z","journal-title":"BMC Urol"},{"key":"1435_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/00000658-194007000-00016","volume":"112","author":"OV Batson","year":"1940","unstructured":"Batson OV (1940) The function of the vertebral veins and their role in the spread of metastases. Ann Surg 112:138\u2013149. https:\/\/doi.org\/10.1097\/00000658-194007000-00016","journal-title":"Ann Surg"},{"key":"1435_CR5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf L, Sch\u00f6pfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578\u2013583. https:\/\/doi.org\/10.1053\/hp.2000.6698","journal-title":"Hum Pathol"},{"key":"1435_CR6","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/pros.23645","volume":"78","author":"E Francini","year":"2018","unstructured":"Francini E, Gray KP, Xie W, Shaw GK, Valen\u00e7a L, Bernard B, Albiges L, Harshman LC, Kantoff PW, Taplin ME, Sweeney CJ (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78:889\u2013895. https:\/\/doi.org\/10.1002\/pros.23645","journal-title":"Prostate"},{"key":"1435_CR7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/bju.13938","volume":"120","author":"A De Bruycker","year":"2017","unstructured":"De Bruycker A, Lambert B, Claeys T, Delrue L, Mbah C, De Meerleer G, Villeirs G, De Vos F, De Man K, Decaestecker K, Fonteyne V, Lumen N, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, Duthoy W, Ost P (2017) Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. BJU Int 120:815\u2013821. https:\/\/doi.org\/10.1111\/bju.13938","journal-title":"BJU Int"},{"key":"1435_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.radonc.2016.07.021","volume":"121","author":"S Sridharan","year":"2016","unstructured":"Sridharan S, Steigler A, Spry NA, Joseph D, Lamb DS, Matthews JH, Atkinson C, Tai KH, Duchesne G, Christie D, Attia J, Holliday EG, Denham JW (2016) Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiother Oncol 121:98\u2013102. https:\/\/doi.org\/10.1016\/j.radonc.2016.07.021","journal-title":"Radiother Oncol"},{"key":"1435_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8\u201310. https:\/\/doi.org\/10.1200\/JCO.1995.13.1.8","journal-title":"J Clin Oncol"},{"key":"1435_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/s0094-0143(05)70385-2","volume":"24","author":"CT Lee","year":"1997","unstructured":"Lee CT, Oesterling JE (1997) Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 24:389\u2013394. https:\/\/doi.org\/10.1016\/s0094-0143(05)70385-2","journal-title":"Urol Clin North Am"},{"key":"1435_CR11","unstructured":"EAU guidelines 2022 Prostate Cancer In. https:\/\/uroweb.org\/guidelines\/prostate-cancer"},{"key":"1435_CR12","doi-asserted-by":"publisher","first-page":"e000037","DOI":"10.1136\/esmoopen-2016-000037","volume":"1","author":"H Shibata","year":"2016","unstructured":"Shibata H, Kato S, Sekine I, Abe K, Araki N et al (2016) Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese orthopedic association, Japanese Urological Association, and Japanese Society for Radiation Oncology. ESMO Open 1:e000037","journal-title":"ESMO Open"},{"key":"1435_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2463\/mrms.4.11","volume":"4","author":"K Nakanishi","year":"2005","unstructured":"Nakanishi K, Kobayashi M, Takahashi S, Nakata S, Kyakuno M, Nakaguchi K, Nakamura H (2005) Whole body MRI for detecting metastatic bone tumor: comparison with bone scintigrams. Magn Reson Med Sci 4:11\u201317. https:\/\/doi.org\/10.2463\/mrms.4.11","journal-title":"Magn Reson Med Sci"},{"key":"1435_CR14","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s00330-002-1344-z","volume":"12","author":"TC Lauenstein","year":"2002","unstructured":"Lauenstein TC, Freudenberg LS, Goehde SC, Ruehm SG, Goyen M, Bosk S, Debatin JF, Barkhausen J (2002) Whole-body MRI using a rolling table platform for the detection of bone metastases. Eur Radiol 12:2091\u20132099. https:\/\/doi.org\/10.1007\/s00330-002-1344-z","journal-title":"Eur Radiol"},{"key":"1435_CR15","first-page":"275","volume":"22","author":"T Takahara","year":"2004","unstructured":"Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22:275\u2013282","journal-title":"Radiat Med"},{"key":"1435_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/jmri.27485","volume":"55","author":"S Van Nieuwenhove","year":"2022","unstructured":"Van Nieuwenhove S, Van Damme J, Padhani AR, Vandecaveye V, Tombal B, Wuts J, Pasoglou V, Lecouvet FE (2022) Whole-body magnetic resonance imaging for prostate cancer assessment: current status and future directions. J Magn Reson Imaging 55:653\u2013680. https:\/\/doi.org\/10.1002\/jmri.27485","journal-title":"J Magn Reson Imaging"},{"key":"1435_CR17","doi-asserted-by":"publisher","first-page":"7240","DOI":"10.26355\/eurrev_202007_21879","volume":"24","author":"G Sun","year":"2020","unstructured":"Sun G, Zhang YX, Liu F, Tu N (2020) Whole-body magnetic resonance imaging is superior to skeletal scintigraphy for the detection of bone metastatic tumors: a meta-analysis. Eur Rev Med Pharmacol Sci 24:7240\u20137252. https:\/\/doi.org\/10.26355\/eurrev_202007_21879","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1435_CR18","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81\u201385","journal-title":"Clin Cancer Res"},{"key":"1435_CR19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcb.10661","volume":"91","author":"A Ghosh","year":"2004","unstructured":"Ghosh A, Heston WD (2004) Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528\u2013539. https:\/\/doi.org\/10.1002\/jcb.10661","journal-title":"J Cell Biochem"},{"key":"1435_CR20","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1038\/s41598-018-22594-1","volume":"8","author":"S Bravaccini","year":"2018","unstructured":"Bravaccini S, Puccetti M, Bocchini M, Ravaioli S, Celli M, Scarpi E, De Giorgi U, Tumedei MM, Raulli G, Cardinale L, Paganelli G (2018) PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci rep Sci Rep 8:4254. https:\/\/doi.org\/10.1038\/s41598-018-22594-1","journal-title":"Sci rep Sci Rep"},{"key":"1435_CR21","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208\u20131216. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7. (Epub Mar 22 2020)","journal-title":"Lancet"},{"key":"1435_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JU.0000000000001698","volume":"206","author":"KJ Pienta","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, Saperstein L, Preston MA, Alva AS, Patnaik A, Durack JC, Stambler N, Lin T, Jensen J, Wong V, Siegel BA, Morris MJ (2021) A Phase 2\/3 Prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J Urol 206:52\u201361. https:\/\/doi.org\/10.1097\/JU.0000000000001698. (Epub Feb 26 2021)","journal-title":"J Urol"},{"key":"1435_CR23","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N (2016) Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926\u2013937. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.021. (Epub Jun 28 2016)","journal-title":"Eur Urol"},{"key":"1435_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.prro.2017.07.011","volume":"8","author":"JD Evans","year":"2018","unstructured":"Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, Davis BJ (2018) Prostate cancer-specific PET radiotracers: a review on the clinical utility in recurrent disease. Pract Radiat Oncol 8:28\u201339. https:\/\/doi.org\/10.1016\/j.prro.2017.07.011. (Epub Jul 20 2017)","journal-title":"Pract Radiat Oncol"},{"key":"1435_CR25","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.euf.2016.11.002","volume":"4","author":"FE von Eyben","year":"2018","unstructured":"von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G (2018) 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus 4:686\u2013693. https:\/\/doi.org\/10.1016\/j.euf.2016.11.002. (Epub Nov 15 2016)","journal-title":"Eur Urol Focus"},{"key":"1435_CR26","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","volume":"20","author":"J Calais","year":"2019","unstructured":"Calais J, Ceci F, Eiber M, Hope TA, Hofman MS et al (2019) 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol 20:1286\u20131294. https:\/\/doi.org\/10.1016\/S1470-2045(19)30415-2. (Epub Jul 30 2019)","journal-title":"Lancet Oncol"},{"key":"1435_CR27","doi-asserted-by":"publisher","first-page":"919","DOI":"10.14670\/HH-18-215","volume":"35","author":"C Van de Wiele","year":"2020","unstructured":"Van de Wiele C, Sathekge M, de Spiegeleer B, De Jonghe PJ, Debruyne PR, Borms M, Beels L, Maes A (2020) PSMA expression on neovasculature of solid tumors. Histol Histopathol 35:919\u2013927. https:\/\/doi.org\/10.14670\/HH-18-215","journal-title":"Histol Histopathol"},{"key":"1435_CR28","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.117.204677","volume":"59","author":"C Rischpler","year":"2018","unstructured":"Rischpler C, Beck TI, Okamoto S, Schlitter AM, Knorr K, Schwaiger M, Gschwend J, Maurer T, Meyer PT, Eiber M (2018) 68Ga-PSMA-HBED-CC uptake in cervical, celiac and sacral ganglia as an important pitfall in prostate cancer PET imaging. J Nucl Med 59:1406\u20131411. https:\/\/doi.org\/10.2967\/jnumed.117.204677","journal-title":"J Nucl Med"},{"key":"1435_CR29","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1007\/s00259-022-05745-5","volume":"49","author":"B Vollnberg","year":"2022","unstructured":"Vollnberg B, Alberts I, Genitsch V, Rominger A, Afshar-Oromieh A (2022) Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET\/CT for prostate cancer-a single-centre experience of PET-guided biopsies. Eur J Nucl Med Mol Imaging 49:3910\u20133916. https:\/\/doi.org\/10.1007\/s00259-022-05745-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1435_CR30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdu519","volume":"26","author":"MR Smith","year":"2015","unstructured":"Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, Chi KN, Balakumaran A, Wei R, Wang H, Braun A, Fizazi K (2015) Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol 26:368\u2013374. https:\/\/doi.org\/10.1093\/annonc\/mdu519","journal-title":"Ann Oncol"},{"key":"1435_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/pcan.2011.7","volume":"14","author":"N Sathiakumar","year":"2011","unstructured":"Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, Blackburn J, Arora T, Kilgore ML (2011) Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US medicare beneficiaries, 1999\u20132006. Prostate Cancer Prostatic Dis 14:177\u2013183. https:\/\/doi.org\/10.1038\/pcan.2011.7","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1435_CR32","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1200\/JCO.19.03148","volume":"38","author":"PJ Saylor","year":"2020","unstructured":"Saylor PJ, Rumble RB, Tagawa S, Eastham JA, Finelli A, Reddy PS, Kungel TM, Nissenberg MG, Michalski JM (2020) Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a cancer care Ontario guideline. J Clin Oncol 38:1736\u20131743. https:\/\/doi.org\/10.1200\/JCO.19.03148","journal-title":"J Clin Oncol"},{"key":"1435_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","volume":"7","author":"PS Lutz","year":"2017","unstructured":"Lutz PS, Balboni T, Jones J, Lo S, Petit J, Rich SE, Wong R, Hahn C (2017) Palliative radiation therapy for bone metastases: update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol 7:4 (Epub 2016 Aug 5)","journal-title":"Pract Radiat Oncol"},{"key":"1435_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1200\/JCO.2018.78.1211","volume":"37","author":"AJ Lawton","year":"2019","unstructured":"Lawton AJ, Lee KA, Cheville AL, Ferrone ML, Rades D, Balboni TA, Abrahm JL (2019) Assessment and management of patients with metastatic spinal cord compression: a multidisciplinary review. J Clin Oncol 37:61\u201371. https:\/\/doi.org\/10.1200\/JCO.2018.78.1211","journal-title":"J Clin Oncol"},{"key":"1435_CR35","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1359\/jbmr.1997.12.10.1539","volume":"12","author":"HM Frost","year":"1997","unstructured":"Frost HM (1997) On our age-related bone loss: insights from a new paradigm. J Bone Miner Res 12:1539\u20131546. https:\/\/doi.org\/10.1359\/jbmr.1997.12.10.1539","journal-title":"J Bone Miner Res"},{"key":"1435_CR36","unstructured":"Janssen Biotech, Inc (2018) Zytiga (abiraterone acetate) [prescribing information]. http:\/\/www.zytiga.com"},{"key":"1435_CR37","unstructured":"Astellas Pharma US, Inc (2018) Xtandi (enzalutamide) [prescribing information]. http:\/\/www.xtandi.com"},{"key":"1435_CR38","unstructured":"Janssen (2018) Products. Erleada (apalutamide) [prescribing information]. http:\/\/www.erleada.com"},{"key":"1435_CR39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11864-014-0320-6","volume":"16","author":"C Ndibe","year":"2015","unstructured":"Ndibe C, Wang CG, Sonpavde G (2015) Corticosteroids in the management of prostate cancer: a critical review. Curr Treat Options Oncol 16:6. https:\/\/doi.org\/10.1007\/s11864-014-0320-6","journal-title":"Curr Treat Options Oncol"},{"key":"1435_CR40","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","volume":"39","author":"TP van Staa","year":"2000","unstructured":"van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol (Oxf Engl) 39:1383\u20131389. https:\/\/doi.org\/10.1093\/rheumatology\/39.12.1383","journal-title":"Rheumatol (Oxf Engl)"},{"key":"1435_CR41","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","volume":"32","author":"MR Smith","year":"2014","unstructured":"Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143\u20131150. https:\/\/doi.org\/10.1200\/JCO.2013.51.6500","journal-title":"J Clin Oncol"},{"key":"1435_CR42","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) A randomised, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in men with castration-resistant prostate cancer. Lancet 377:813\u2013822. https:\/\/doi.org\/10.1016\/S0140-6736(10)62344-6","journal-title":"Lancet"},{"key":"1435_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"MR Smith","year":"2012","unstructured":"Smith MR, Saad F, Coleman R, Shore N, Fizazi K et al (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379:39\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(11)61226-9","journal-title":"Lancet"},{"key":"1435_CR44","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00774-020-01151-9","volume":"39","author":"Y Nakai","year":"2021","unstructured":"Nakai Y, Kanaki T, Yamamoto A, Tanaka R, Yamamoto Y, Nagahara A, Nakayama M, Kakimoto KI, Ishibashi M, Nishimura K (2021) Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents. J Bone Miner Metab 39:295\u2013301. https:\/\/doi.org\/10.1007\/s00774-020-01151-9","journal-title":"J Bone Miner Metab"},{"key":"1435_CR45","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O\u2019Connor T, Velasco MR, Weckstein D, O\u2019Mara A, Loprinzi CL, Shapiro CL (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 317:48\u201358. https:\/\/doi.org\/10.1001\/jama.2016.19425","journal-title":"JAMA"},{"key":"1435_CR46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","volume":"35","author":"T Yoneda","year":"2017","unstructured":"Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S, Toyosawa S (2017) Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 35:6\u201319. https:\/\/doi.org\/10.1007\/s00774-016-0810-7","journal-title":"J Bone Miner Metab"},{"key":"1435_CR47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13014-021-01776-8","volume":"16","author":"P Rogowski","year":"2021","unstructured":"Rogowski P, Roach M, Schmidt-Hegemann NS, Trapp C, von Bestenbostel R, Shi R, Buchner A, Stief C, Belka C, Li M (2021) Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol 16:50. https:\/\/doi.org\/10.1186\/s13014-021-01776-8","journal-title":"Radiat Oncol"},{"key":"1435_CR48","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.euo.2018.09.005","volume":"2","author":"A Battaglia","year":"2019","unstructured":"Battaglia A, De Meerleer G, Tosco L, Moris L, Van den Broeck T, Devos G, Everaerts W, Joniau S (2019) Novel insights into the management of oligometastatic prostate cancer: a comprehensive review. Eur Urol Oncol 2:174\u2013188. https:\/\/doi.org\/10.1016\/j.euo.2018.09.005","journal-title":"Eur Urol Oncol"},{"key":"1435_CR49","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, De Meerleer G (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter Phase II trial. J Clin Oncol 36:446\u2013453. https:\/\/doi.org\/10.1200\/JCO.2017.75.4853","journal-title":"J Clin Oncol"},{"key":"1435_CR50","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE Phase 2 randomized clinical trial. JAMA Oncol 6:650\u2013659. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0147","journal-title":"JAMA Oncol"},{"key":"1435_CR51","first-page":"341","volume":"26","author":"PJ Cheetham","year":"2012","unstructured":"Cheetham PJ, Petrylak DP (2012) Alpha particles as radiopharmaceuticals in the treatment of bone metastases:mechanism of action of radium-223 chloride (Alpharadin) and radiation protection. Oncol (Williston Park) 26:341","journal-title":"Oncol (Williston Park)"},{"key":"1435_CR52","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1158\/1078-0432.CCR-16-2955","volume":"23","author":"MI Suominen","year":"2017","unstructured":"Suominen MI, Fagerlund KM, Rissanen JP, Konkol YM, Morko JP, Peng Z, Alhoniemi EJ, Laine SK, Corey E, Mumberg D, Ziegelbauer K, K\u00e4k\u00f6nen SM, Halleen JM, Vessella RL, Scholz A (2017) Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models. Clin Cancer Res 23:4335\u20134346. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2955","journal-title":"Clin Cancer Res"},{"key":"1435_CR53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213\u2013223. https:\/\/doi.org\/10.1056\/NEJMoa1213755","journal-title":"N Engl J Med"},{"key":"1435_CR54","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","volume":"15","author":"O Sartor","year":"2014","unstructured":"Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI et al (2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 15:738\u2013746. https:\/\/doi.org\/10.1016\/S1470-2045(14)70183-4. (Epub May 13 2014)","journal-title":"Lancet Oncol"},{"key":"1435_CR55","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","volume":"20","author":"M Smith","year":"2019","unstructured":"Smith M, Parker C, Saad F, Miller K, Tombal B et al (2019) Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:408\u2013419. https:\/\/doi.org\/10.1016\/S1470-2045(18)30860-X","journal-title":"Lancet Oncol"},{"key":"1435_CR56","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1200\/JCO.2019.37.15_suppl.5007","volume":"37","author":"BF Tombal","year":"2019","unstructured":"Tombal BF, Loriot Y, Saad F, McDermott RS, Elliott T, Rodriguez-Vida A, Nole F, Fournier B, Collette L, Gillessen S (2019) Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333\/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis. J Clin Oncol 37:5007. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.5007","journal-title":"J Clin Oncol"},{"key":"1435_CR57","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.euo.2019.02.007","volume":"3","author":"JM O\u2019Sullivan","year":"2020","unstructured":"O\u2019Sullivan JM, Carles J, Cathomas R, Gomez-Iturriaga A, Heinrich D, Kramer G, Ost P, van Oort I, Tombal B (2020) Radium-223 within the evolving treatment options for metastatic castration-resistant prostate cancer: recommendations from a European expert working group. Urol Oncol 3:455\u2013463. https:\/\/doi.org\/10.1016\/j.euo.2019.02.007","journal-title":"Urol Oncol"},{"key":"1435_CR58","unstructured":"NCCN guidelines, version 4.2022 Prostate Cancer In. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"key":"1435_CR59","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(16)30173-5","volume":"17","author":"F Saad","year":"2016","unstructured":"Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, L\u00e9vy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O\u2019Sullivan JM, Radium-223 International Early Access Program Investigators (2016) Radium-223 International Early Access Program Investigators:radium-223 and concomitant therapies in patients with metastatic castration\u2014resistant prostate cancer: an international, Early access, open-label, single-arm phase 3b trial. Lancet Oncol 17:1306\u20131316. https:\/\/doi.org\/10.1016\/S1470-2045(16)30173-5","journal-title":"Lancet Oncol"},{"key":"1435_CR60","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s10147-020-01776-w","volume":"26","author":"Y Yamamoto","year":"2021","unstructured":"Yamamoto Y, Okuda Y, Kanaki T, Tanaka R, Nagahara A, Nakai Y, Nakayama M, Kakimoto KI, Nishimura K (2021) Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases. Int J Clin Oncol 26:192\u2013198. https:\/\/doi.org\/10.1007\/s10147-020-01776-w","journal-title":"Int J Clin Oncol"},{"key":"1435_CR61","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2214\/AJR.18.20845","volume":"213","author":"MP Yadav","year":"2019","unstructured":"Yadav MP, Ballal S, Sahoo RK, Dwivedi SN, Bal C (2019) Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 213:275\u2013285. https:\/\/doi.org\/10.2214\/AJR.18.20845. (Epub Apr 17 2019)","journal-title":"AJR Am J Roentgenol"},{"key":"1435_CR62","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385:1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"key":"1435_CR63","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM et al (2021) 177Lu. Philippine Sugar Millers Association, Lu-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397:797\u2013804","journal-title":"Lancet"},{"key":"1435_CR64","doi-asserted-by":"publisher","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Francis RJ, Gedye C, Rutherford NK, Zhang AY, McJannett MM, Stockler MR, Williams S, Martin AJ, Davis ID (2022) TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel\u2014overall survival after median follow-up of 3 years (ANZUP 1603). Abstract. J Clin Oncol 40(16_suppl) (suppl 16; abstr 5000). https:\/\/meetings.asco.org\/2022-asco-annual-meeting\/14368?presentation=207021#207021 Accessed 22 Jun 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.5000","DOI":"10.1200\/JCO.2022.40.16_suppl.5000"},{"key":"1435_CR65","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H et al (2021) Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol 22:1115\u20131125. https:\/\/doi.org\/10.1016\/S1470-2045(21)00274-6","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"1435_CR66","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","volume":"40","author":"P Kuo","year":"2022","unstructured":"Kuo P, Hesterman J, Rahbar K, Kendi AT, Wei XX, Fang B, Adra N, Armstrong AJ, Garje R, Michalski JM, Ghebremariam S, Brackman M, Wong C, Benson T, Vogelzang NJ (2022) [68Ga] Philippine Sugar Millers Association, GA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a VISION substudy (abstract). J Clin Oncol 40(16_suppl):5002","journal-title":"J Clin Oncol"},{"key":"1435_CR67","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Th\u00e9odore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502\u20131512. https:\/\/doi.org\/10.1056\/NEJMoa040720","journal-title":"N Engl J Med"},{"key":"1435_CR68","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995\u20132005. https:\/\/doi.org\/10.1056\/NEJMoa1014618","journal-title":"N Engl J Med"},{"key":"1435_CR69","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187\u20131197. https:\/\/doi.org\/10.1056\/NEJMoa1207506","journal-title":"N Engl J Med"},{"key":"1435_CR70","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, Investigators TROPIC (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147\u20131154. https:\/\/doi.org\/10.1016\/S0140-6736(10)61389-X","journal-title":"Lancet"},{"key":"1435_CR71","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, \u00d6zg\u00fcro\u011flu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN, LATITUDE Investigators (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352\u2013360. https:\/\/doi.org\/10.1056\/NEJMoa1704174","journal-title":"N Engl J Med"},{"key":"1435_CR72","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A (2019) ARCHES: a randomized, Phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37:2974\u20132986. https:\/\/doi.org\/10.1200\/JCO.19.00799","journal-title":"J Clin Oncol"},{"key":"1435_CR73","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, de Santana P et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381:13\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1903307","journal-title":"N Engl J Med"},{"key":"1435_CR74","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K,\u00a0Foulon S, Carles J, Roubaud G, McDermott R et al (2022) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet 399:1695\u20131707. https:\/\/doi.org\/10.1016\/S0140-6736(22)00367-1","journal-title":"Lancet"},{"key":"1435_CR75","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386:1132\u20131142. https:\/\/doi.org\/10.1056\/NEJMoa2119115","journal-title":"N Engl J Med"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-023-01435-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-023-01435-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-023-01435-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:25:50Z","timestamp":1685319950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-023-01435-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1435"],"URL":"https:\/\/doi.org\/10.1007\/s00774-023-01435-w","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"29 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Nishimura has received speaker honoraria from Astellas, AstraZeneca, and Bayer; in addition to research funding from Bayer outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Approval of the research protocol by an Institutional Review Board"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registry and the registration no. of the study\/trial"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal study"}}]}}